Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07108114 · ClinicalTrials.gov registry record · Phase 1
SLV-324 Treatment of Metastatic Solid Tumors
A Phase 1 study of Metastatic Solid Tumors, sponsored by Solve Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
- 7
- Study locations
NCT07108114 is a Phase 1 study of Metastatic Solid Tumors that is actively recruiting participants, run by Solve Therapeutics. The registered enrollment target is 70 participants, below the 203-participant average among 20 other Metastatic Solid Tumors trials with a reported enrollment target (66% lower). The trial reports 7 study locations across 6 states.
The verdict
NCT07108114, a Phase 1 study of Metastatic Solid Tumors, is actively recruiting participants, sponsored by Solve Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
- 7
- Study locations
Study Summary
This is a Phase 1 dose-escalation study evaluating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of SLV-324 across a range of dose levels when administered to subjects with metastatic solid tumors.
Conditions Studied
Interventions
- DRUG SLV-324 intravenous (IV infusion)
Study Locations (7)
Texas
- MD Anderson Cancer Center - Houston
- Mays Cancer Center; University of Texas Health San Antonio - Houston
California
- Hoag Memorial Hospital Presbyterian - Newport Beach
Missouri
- Washington University - St Louis
Ohio
- University Hospitals Cleveland Medical Center - Cleveland
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Washington
- University of Washington / Fred Hutchinson Cancer Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2025-08-25 |
| Est. Completion | 2027-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07108114
The ClinicalTrials.gov registry entry for NCT07108114 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 203-participant average among 20 other Metastatic Solid Tumors trials with a reported enrollment target (66% lower). The listed sponsor is Solve Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which SLV-324 intravenous (IV infusion) is the first listed.
NCT07108114 reports 7 study locations spanning 6 distinct geographic areas - top geographies include Texas, California, Missouri.
Frequently Asked Questions
What is clinical trial NCT07108114 about?
NCT07108114 is a clinical study titled "SLV-324 Treatment of Metastatic Solid Tumors". This is a Phase 1 dose-escalation study evaluating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of SLV-324 across a range of dose levels when administered to subjects with metastatic solid tumors.
What is the current status of trial NCT07108114?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2025-08-25. Estimated completion is 2027-08.
What conditions does trial NCT07108114 study?
This clinical trial studies the following conditions: Metastatic Solid Tumors.
What interventions are being tested in trial NCT07108114?
The interventions under investigation include: SLV-324 intravenous (IV infusion) (DRUG).
Who is sponsoring clinical trial NCT07108114?
This trial is sponsored by Solve Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07108114 being conducted?
This trial has 7 study locations across California, Missouri, Ohio, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
RECRUITING · Phase 1
-
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.